Full Press Release Details
QED And Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability And Activity Of Low-dose Infigratinib In Treating Achondroplasia.
BBIO
QED And Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability And Activity Of Low-dose Infigratinib In Treating Achondroplasia
Key Takeaway: QED And Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability And Activity Of Low-dose Infigratinib In Treating Achondroplasia
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis